European journal of neurology · 2025
The Facioscapulohumeral Muscular Dystrophy Rasch-Built Overall Disability Scale (FSHD-RODS): Longitudinal Assessment of a Disease-Specific Patient Reported Outcome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Teeselink Sjan, Vincenten Sanne C C, Voermans Nicol C, van Alfen Nens, van Engelen Baziel G M, Mul Karlien
Аннотация
OBJECTIVE: To assess changes in the facioscapulohumeral muscular dystrophy Rasch-Built Overall Disability Scale (FSHD-RODS) over 6.5 years in FSHD patients.
METHODS: FSHD patients of 18 years or older were assessed at baseline (T1) and followed up at 5 years (T2) and 6.5 years (T3). The patient-reported FSHD-RODS and Sickness Impact Profile 68 (SIP68) questionnaires were evaluated, alongside the FSHD clinical severity score, FSHD clinical score and Motor Function Measure (MFM). Individual minimal clinically important differences (MCID-SE) of the FSHD-RODS were calculated to assess the clinical importance of the change over time. A subgroup analysis included patients eligible for current clinical trials.
RESULTS: Sixty-two patients were included, representing the full disease spectrum. The FSHD-RODS and SIP68 questionnaire outcomes remained stable, whereas overall disease severity slightly increased (FSHD clinical severity score 6 to 6.5, p < 0.001) and MFM slightly decreased (94% to 91%, p < 0.001). FSHD-RODS correlated strongly with SIP68, MFM and disease severity (ρ ≥ 0.69). The clinical trial subgroup (n = 33) showed similar results. Ten patients (16%), all with moderate-to-severe baseline disease (FSHD clinical severity score ≥ 6), showed clinically important deterioration over 6.5 years.
CONCLUSIONS: FSHD progression is generally slow, with FSHD-RODS only detecting meaningful decline in moderately to severely affected patients. The ability to compensate for muscle weakness may limit the sensitivity of patient-reported outcomes like FSHD-RODS in clinical trials. These findings highlight the need for alternative measures to capture disease progression and treatment effects in FSHD research.
METHODS: FSHD patients of 18 years or older were assessed at baseline (T1) and followed up at 5 years (T2) and 6.5 years (T3). The patient-reported FSHD-RODS and Sickness Impact Profile 68 (SIP68) questionnaires were evaluated, alongside the FSHD clinical severity score, FSHD clinical score and Motor Function Measure (MFM). Individual minimal clinically important differences (MCID-SE) of the FSHD-RODS were calculated to assess the clinical importance of the change over time. A subgroup analysis included patients eligible for current clinical trials.
RESULTS: Sixty-two patients were included, representing the full disease spectrum. The FSHD-RODS and SIP68 questionnaire outcomes remained stable, whereas overall disease severity slightly increased (FSHD clinical severity score 6 to 6.5, p < 0.001) and MFM slightly decreased (94% to 91%, p < 0.001). FSHD-RODS correlated strongly with SIP68, MFM and disease severity (ρ ≥ 0.69). The clinical trial subgroup (n = 33) showed similar results. Ten patients (16%), all with moderate-to-severe baseline disease (FSHD clinical severity score ≥ 6), showed clinically important deterioration over 6.5 years.
CONCLUSIONS: FSHD progression is generally slow, with FSHD-RODS only detecting meaningful decline in moderately to severely affected patients. The ability to compensate for muscle weakness may limit the sensitivity of patient-reported outcomes like FSHD-RODS in clinical trials. These findings highlight the need for alternative measures to capture disease progression and treatment effects in FSHD research.